SG11202006125VA - Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors - Google Patents
Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitorsInfo
- Publication number
- SG11202006125VA SG11202006125VA SG11202006125VA SG11202006125VA SG11202006125VA SG 11202006125V A SG11202006125V A SG 11202006125VA SG 11202006125V A SG11202006125V A SG 11202006125VA SG 11202006125V A SG11202006125V A SG 11202006125VA SG 11202006125V A SG11202006125V A SG 11202006125VA
- Authority
- SG
- Singapore
- Prior art keywords
- pyridin
- methyl
- ghrelin
- goat
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154824 | 2018-02-02 | ||
| PCT/EP2019/051989 WO2019149657A1 (fr) | 2018-02-02 | 2019-01-28 | Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006125VA true SG11202006125VA (en) | 2020-07-29 |
Family
ID=61157050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006125VA SG11202006125VA (en) | 2018-02-02 | 2019-01-28 | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11254688B2 (fr) |
| EP (1) | EP3746451B1 (fr) |
| JP (1) | JP7015396B2 (fr) |
| KR (1) | KR20200116978A (fr) |
| CN (1) | CN111655700B (fr) |
| AU (1) | AU2019215707A1 (fr) |
| BR (1) | BR112020013082A2 (fr) |
| CA (1) | CA3087826A1 (fr) |
| CL (1) | CL2020001907A1 (fr) |
| CO (1) | CO2020009299A2 (fr) |
| CR (1) | CR20200332A (fr) |
| EA (1) | EA202091805A1 (fr) |
| EC (1) | ECSP20050785A (fr) |
| IL (1) | IL276136A (fr) |
| JO (1) | JOP20200190A1 (fr) |
| MA (1) | MA53075A (fr) |
| MX (1) | MX2020008053A (fr) |
| PE (1) | PE20210174A1 (fr) |
| PH (1) | PH12020551168A1 (fr) |
| SG (1) | SG11202006125VA (fr) |
| WO (1) | WO2019149657A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037277B1 (ru) | 2016-08-05 | 2021-03-03 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat) |
| SG11202006302TA (en) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| MX2020008053A (es) | 2018-02-02 | 2020-09-07 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). |
| JP7225253B2 (ja) * | 2018-02-02 | 2023-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体 |
| WO2021233884A1 (fr) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Procédé continu de fabrication de 7-amino-5-méthyl-[1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle |
| JP2023526351A (ja) | 2020-05-22 | 2023-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法 |
| WO2023114472A1 (fr) * | 2021-12-16 | 2023-06-22 | Icahn School Of Medicine At Mount Sinai | Composés hétérocycliques en tant qu'agonistes polarisés 5ht2a |
| CN114426516B (zh) * | 2022-02-16 | 2022-11-04 | 安徽有吉医药科技有限公司 | 一种2-氨基-3-溴吡啶的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082383A1 (fr) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Utilisation de triazolopyrimidines pour combattre les nematodoses de vegetaux |
| WO2008008286A2 (fr) | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Pyrazoles substitués servant d'antagonistes des récepteurs de la ghréline |
| US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| CA2684037C (fr) | 2007-04-11 | 2016-02-16 | Canbas Co., Ltd. | Composes presentant une activite anti-cancereuse |
| JP2010527951A (ja) | 2007-05-24 | 2010-08-19 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体 |
| WO2008152403A1 (fr) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Analogues du glucagon |
| FR2934058B1 (fr) | 2008-07-15 | 2010-09-24 | Centre Nat Rech Scient | Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines |
| FR2933989B1 (fr) | 2008-07-16 | 2013-03-08 | Commissariat Energie Atomique | Procede de purification de microorganismes presents dans des echantillons liquides |
| FR2933975B1 (fr) | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| EP2370459A1 (fr) | 2008-12-15 | 2011-10-05 | Zealand Pharma A/S | Analogues du glucagon |
| CN102282166B (zh) | 2008-12-15 | 2015-04-01 | 西兰制药公司 | 胰高血糖素类似物 |
| EA020520B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
| DK2370462T3 (da) | 2008-12-15 | 2014-09-08 | Zealand Pharma As | Glucagon-analoger |
| SG177609A1 (en) | 2009-07-13 | 2012-02-28 | Zealand Pharma As | Acylated glucagon analogues |
| US20110078154A1 (en) | 2009-09-28 | 2011-03-31 | Accenture Global Services Gmbh | Recruitment screening tool |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| MX2012014961A (es) | 2010-06-24 | 2013-02-26 | Zealand Pharma As | Analogos de glucagon. |
| EP2793931A2 (fr) | 2011-12-23 | 2014-10-29 | Zealand Pharma A/S | Analogues du glucagon |
| US9238639B2 (en) | 2012-02-24 | 2016-01-19 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| EP2863910B1 (fr) * | 2012-06-20 | 2020-03-11 | University Of Virginia Patent Foundation | Compositions et procédés pour réguler l'homéostasie du glucose et l'action de l'insuline |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| US20170275249A1 (en) | 2014-09-17 | 2017-09-28 | The Regents Of The University Of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| EP3250569B1 (fr) * | 2015-01-30 | 2019-01-09 | Boehringer Ingelheim International GmbH | Inhibiteurs de l'aldostérone synthase |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104672A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| FI3364993T3 (fi) | 2015-10-22 | 2023-01-13 | Menetelmiä angelmanin oireyhtymän hoitamiseksi | |
| EA037277B1 (ru) * | 2016-08-05 | 2021-03-03 | Бёрингер Ингельхайм Интернациональ Гмбх | Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat) |
| SG10202101247QA (en) | 2016-08-11 | 2021-03-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of irritable bowel syndrome |
| US10988487B2 (en) | 2016-08-29 | 2021-04-27 | Merck Sharp & Dohme Corp. | Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| SG11202006302TA (en) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| PE20210175A1 (es) | 2018-02-02 | 2021-01-29 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) |
| JP7225253B2 (ja) | 2018-02-02 | 2023-02-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体 |
| MX2020008053A (es) | 2018-02-02 | 2020-09-07 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat). |
-
2019
- 2019-01-28 MX MX2020008053A patent/MX2020008053A/es unknown
- 2019-01-28 EP EP19702246.0A patent/EP3746451B1/fr active Active
- 2019-01-28 SG SG11202006125VA patent/SG11202006125VA/en unknown
- 2019-01-28 CA CA3087826A patent/CA3087826A1/fr not_active Abandoned
- 2019-01-28 JP JP2020541873A patent/JP7015396B2/ja active Active
- 2019-01-28 BR BR112020013082-6A patent/BR112020013082A2/pt not_active Application Discontinuation
- 2019-01-28 US US16/966,483 patent/US11254688B2/en active Active
- 2019-01-28 CR CR20200332A patent/CR20200332A/es unknown
- 2019-01-28 KR KR1020207025417A patent/KR20200116978A/ko unknown
- 2019-01-28 MA MA053075A patent/MA53075A/fr unknown
- 2019-01-28 CN CN201980010416.2A patent/CN111655700B/zh active Active
- 2019-01-28 WO PCT/EP2019/051989 patent/WO2019149657A1/fr unknown
- 2019-01-28 PE PE2020001161A patent/PE20210174A1/es unknown
- 2019-01-28 EA EA202091805A patent/EA202091805A1/ru unknown
- 2019-01-28 JO JOP/2020/0190A patent/JOP20200190A1/ar unknown
- 2019-01-28 AU AU2019215707A patent/AU2019215707A1/en not_active Abandoned
-
2020
- 2020-07-19 IL IL276136A patent/IL276136A/en unknown
- 2020-07-21 CL CL2020001907A patent/CL2020001907A1/es unknown
- 2020-07-28 CO CONC2020/0009299A patent/CO2020009299A2/es unknown
- 2020-07-31 PH PH12020551168A patent/PH12020551168A1/en unknown
- 2020-08-24 EC ECSENADI202050785A patent/ECSP20050785A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020551168A1 (en) | 2021-05-31 |
| PE20210174A1 (es) | 2021-01-29 |
| MA53075A (fr) | 2021-05-12 |
| CO2020009299A2 (es) | 2020-08-21 |
| CA3087826A1 (fr) | 2019-08-08 |
| JOP20200190A1 (ar) | 2020-07-29 |
| EP3746451B1 (fr) | 2023-07-12 |
| JP7015396B2 (ja) | 2022-02-15 |
| WO2019149657A1 (fr) | 2019-08-08 |
| CL2020001907A1 (es) | 2020-10-30 |
| CN111655700A (zh) | 2020-09-11 |
| IL276136A (en) | 2020-09-30 |
| MX2020008053A (es) | 2020-09-07 |
| EP3746451A1 (fr) | 2020-12-09 |
| AU2019215707A1 (en) | 2020-07-09 |
| US11254688B2 (en) | 2022-02-22 |
| US20210053985A1 (en) | 2021-02-25 |
| ECSP20050785A (es) | 2020-09-30 |
| CN111655700B (zh) | 2023-07-18 |
| EA202091805A1 (ru) | 2020-12-16 |
| CR20200332A (es) | 2020-09-03 |
| JP2021512113A (ja) | 2021-05-13 |
| KR20200116978A (ko) | 2020-10-13 |
| BR112020013082A2 (pt) | 2020-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276136A (en) | Benzyl, (pyridin-3-yl)methyl or (pyridin-4-yl)methyl-substituted oxadiazolopyridines as inhibitors of ghrelin O-acyltransferase | |
| IL292644A (en) | ras inhibitors | |
| DK3359541T3 (da) | N-sulfonylerede pyrazol[3,4-b]pyridin-6-carboxamider og fremgangsmåde til anvendelse | |
| SG11202003194YA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11202106304RA (en) | Irreversible inhibitors of menin-mll interaction | |
| PH12016500895B1 (en) | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor | |
| HK1258996A1 (zh) | 新型fyn激酶抑制劑的方法、組合物以及用途 | |
| IL276145A (en) | Triazolopyrimidine history for use as ghrelin O-acyltransferase inhibitors | |
| HK1249504A1 (zh) | 用作溴結構域抑制劑的吡啶酮二甲酰胺 | |
| HK1247613A1 (zh) | 炔基吡啶類脯氨酰羥化酶抑制劑、其製備方法和醫藥用途 | |
| IL264506B (en) | History of oxadiazolopyridine for use as gellin o-acyl transferase inhibitors | |
| ZA201705675B (en) | Ghrelin o-acyl transferase inhibitors | |
| HK1245678A1 (zh) | 使用酪氨酸激酶抑制劑的組合物和方法 | |
| IL276137A (en) | Heterocyclyl-converted oxadiazolopyridine compounds for use as ghrelin O-acyltransferase inhibitors | |
| ZA201705678B (en) | Ghrelin o-acyl transferase inhibitors | |
| ZA201900144B (en) | Heat insulating coating composition, method for applying such coating composition and kit of parts comprising such coating composition | |
| IL272939A (en) | Vinyl heterocycles as RHO-linked coiled-coil kinase inhibitors | |
| SG11202011366SA (en) | Heterocondensed pyridones compounds and their use as idh inhibitors | |
| IL289993A (en) | Ethynyl-heterocycles as rho-bound (rock) roller-bound kinase inhibitors | |
| MX2016009435A (es) | N-aril piridinonas sustituidas. | |
| HUE050352T2 (hu) | Piridin-helyettesített 2-aminopiridin protein kináz inhibitor kristály | |
| ZA201907272B (en) | N-(4-pyridyl)nicotinamide compound or salt thereof | |
| IL288950A (en) | History of pyridine-3-yl | |
| GB201810765D0 (en) | SRPK1 inhibitors | |
| GB201715637D0 (en) | SRPK1 Inhibitors |